| Basics |
Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its products portfolio includes Glybera, TV-45070.
|
| IPO Date: |
November 5, 2014 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$2.42B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.45 | 2.50%
|
| Avg Daily Range (30 D): |
$0.51 | 1.58%
|
| Avg Daily Range (90 D): |
$0.65 | 2.00%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.26M |
| Avg Daily Volume (30 D): |
.78M |
| Avg Daily Volume (90 D): |
.85M |
| Trade Size |
| Avg Trade Size (Sh.): |
85 |
| Avg Trade Size (Sh.) (30 D): |
60 |
| Avg Trade Size (Sh.) (90 D): |
65 |
| Institutional Trades |
| Total Inst.Trades: |
2,283 |
| Avg Inst. Trade: |
$1.62M |
| Avg Inst. Trade (30 D): |
$4.52M |
| Avg Inst. Trade (90 D): |
$2.65M |
| Avg Inst. Trade Volume: |
.05M |
| Avg Inst. Trades (Per Day): |
2 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.68M |
| Avg Closing Trade (30 D): |
$10.37M |
| Avg Closing Trade (90 D): |
$5.06M |
| Avg Closing Volume: |
48.59K |
|
|
| Financials |
| |
TTM |
Q1 2025 |
Q3 2024 |
|
Basic EPS
|
|
$-.83
|
$-.81
|
|
Diluted EPS
|
|
$-.83
|
$-.81
|
|
Revenue
|
$
|
$ 7.5M
|
$ M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$
|
$ -65.05M
|
$ -62.79M
|
|
Operating Income / Loss
|
$
|
$ -72.74M
|
$ -73.68M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$
|
$ -26.06M
|
$ -.05M
|
|
PE Ratio
|
|
|
|
|
|
|
